MERCK
Merck’s Consumer Health business has finished 2014 with robust financial performance. Entering 2015, this year marks 80 years since the launch of Merck’s Seven Seas brand in the UK, reflecting the firm’s rich heritage of product innovation and development.
80 years of success
2015 is exactly 80 years since the launch of Merck’s Seven Seas franchise – a company originally created by a consortium of trawler owners in East Yorkshire, England to produce fish oil supplements on highest purity levels. Since its foundation in 1935, Seven Seas has become a household name, supplying a diverse range of products in more than 100 countries worldwide. The brand continues to innovate and launch even more consumer focused solutions, best demonstrated by the launch of Perfect 7 in fall 2014.
“Innovation has been a consistent force behind Merck Consumer Health’s success, including throughout the 80 years of heritage celebrated this year for Seven Seas.” said Uta Kemmerich-Keil, CEO and President of Merck’s Consumer Health business. “This has been recognized by consumers and we remain committed to meeting changing habits and preferences, as we grow our business in 2015. We are intensively listening to and learning from consumer feedback, as our financial success is reliant on constantly improving our product offer along the consumer’s desires.”
This approach has recently also resulted in external recognition for the Seven Seas brand: Seven Seas Perfect 7, an innovative and unique blend of Omega-3 oils, vitamins and minerals specifically tailored to the nutritional needs of men and women, has received a prestigious Boots Vitamin Award in the UK as the ‘newcomer of the year’ for 2014, reflecting its popularity with consumers.
The award and product performance are indicative of Merck Consumer Health’s approach to innovation. The business is driving this through its new innovation portal, www.merck-consumer-idea.com , where consumers can now provide their thoughts on how future products could help meet their health needs. In the spirit of co-creation, the portal has already begun to capture feedback on how consumers feel that existing products could be tailored more to their needs.
Integration on track
Merck’s Consumer Health business is continuing to also benefit from product integration from Merck Serono, and this year will see the full transfer of the Vitamin D supplement Vigantoletten from Merck Serono to the Consumer Health business. This product, which is also now sold in Germany in an innovative powder format (“Vigantoletten Sticks”), has made a successful transition from the prescription to over-the-counter setting marketing.
Fastest growing Merck division in 2014
In the final quarter of 2014, the Consumer Health division reported organic growth of 6.5% to € 196.9 million compared with the same period in 2013. Key brands driving this growth include Neurobion, Femibion and Floratil; key markets growing well were Brazil, Venezuela and Germany.
For the full year 2014, Consumer Health demonstrated the ongoing success of its consumer-centric business model and the consumerization of the Neurobion and Floratil brands. With organic sales growth of 5.4% up to € 766 million (2013: € 742 million) Consumer Health was the fastest growing division in the Merck Group. EBITDA pre one-time items came in at € 169 million nearly reaching the 2013 earnings level of € 172 million despite significantly higher marketing and sales investments into the strategic brands.
About Merck’s Consumer Health Business
Brands of the Consumer Health business, such as Dolo-Neurobion® , Neurobion® , Bion® , Seven Seas® , Nasivin® , and Femibion® are innovative leaders in key markets, backed by science and trusted by consumers worldwide. The Consumer Health business is with over 2,600 employees globally active in over 40 markets. Since 2014, the portfolio comprises of brands with annual total sales of about $ 1 billion. Consumer Health is a business of the Healthcare business sector within the Merck Group with global headquarters in Darmstadt, Germany. For more information please go to www.meck-consumer-health.com
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading company for innovative, top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of around € 11.3 billion in 2014. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
Contact:
Merck Consumer Health
Lars Atorf
Phone: +49 6151 856 3114
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Art Collective teamLab to Open New Museum, teamLab Biovortex Kyoto on October 7, 20257.8.2025 08:00:00 CEST | Press release
Unveiling 7 artworks, including pieces never before exhibited in Japan. Tickets on Sale now teamLab Biovortex Kyoto, art collective teamLab’s permanent art museum, is set to open in Minami-ku, Kyoto, as part of the Kyoto Station Southeast Area Project on October 7, 2025. This will be teamLab's largest museum in Japan, spanning over 10,000 square meters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806347101/en/ Even if individual elements are separated in space and time, when a structural order appears among them, the elements transcend space and time and form a single entity. Despite significant changes in shape or size on the surface, or even if all of the elements are replaced, the single existence will be maintained. This spatiotemporal existence is part of the whole, it appears from the whole, and is returned to it. It is a living universe - a biocosmos. (teamLab, Morphing Continuum © teamLab) In preparation for th
Allianz Announces Excellent Performance and Is Fully on Track for Full-year Ambitions7.8.2025 07:13:00 CEST | Press release
2Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250806235547/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Allianz achieves strong growth and record operating profitTotal business volume rises 8.01 percent to 44.5 billion euros, supported by good growth across all segments Operating profit increases 12.2 percent and reaches a record level of 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 17.3 percent and reaches 3.0 billion euros. Adjusted for the 0.3 billion euros disposal gain on the UniCredit Joint Venture, shareholders’ core net income increases 7.1 percent 6M 2025 Excellent performance across our businesses and record operating profitTotal business volume grows 10.1 1 percent and reaches 98.5 billion euros, with contributions from all segments Operating profit increases 9.3 percent to 8.6 billion euros, our highest half-
New pulp mill boosts Suzano's sales and revenue in the second quarter of 20257.8.2025 04:17:00 CEST | Press release
Suzano, the world’s largest pulp producer, announces its results for the second quarter of 2025 (2Q25), reporting sales of 3.7 million tonnes of pulp and paper. Sales increased 28% over the same period in 2024 (2Q24), mainly reflecting the strong operational contribution of the new Ribas do Rio Pardo pulp mill, whose production started in July 2024. Net revenue in the quarter totaled R$13.3 billion, a 16% increase compared to 2Q24. The expansion of pulp production capacity in Brazil, combined with the positive contribution to paper sales from the mills recently acquired in the United States and favorable FX rates, mitigated the impact on net revenue of lower pulp prices in the global market compared to 2Q24. As a result, Suzano's adjusted EBITDA reached R$6.1 billion and operating cash generation totaled R$4.1 billion. Net profit totaled R$5.0 billion positively impacted by the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. Beto
Graanul - Update on the Consent Solicitation and Scheme Solicitation6.8.2025 22:22:00 CEST | Press release
Graanul: Update on the Consent Solicitation and Scheme Solicitation relating to: €250,000,000 Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354015 / Common Code 239735401 Rule 144A Notes: ISIN Number XS2397354288 / Common Code 239735428) (the “Existing Floating Rate Notes”) and €380,000,000 4.625% Sustainability-Linked Senior Secured Notes due 2026 (Regulation S Notes: ISIN Number XS2397354528 / Common Code 239735452 Rule 144A Notes: ISIN Number: XS2397355095 / Common Code 239735509) (the “Existing Fixed Rate Notes” and together with the Existing Floating Rate Notes, the “Existing Notes”) of Cullinan Holdco SCSp a special limited partnership (société en commandite spéciale) established under the laws of Luxembourg, having its registered office at 2, avenue Charles de Gaulle, L-1653, registered with the Luxembourg Register of Commerce and Companies under number B-256979 (the “Issuer” and together with its subsidiaries, “Graanul”
Statement by Aviator LLC6.8.2025 16:18:00 CEST | Press release
Company successfully initiates proceedings following Georgian court victories; UK injunction preserves status quo pending trial Aviator LLC today issued a statement clarifying the nature and scope of a recent UK court ruling following public statements made by SPRIBE OU regarding interim injunction proceedings. According to Nikoloz Gogilidze, legal representative for Aviator LLC, the recent court order was an interim injunction with limited scope and commercial impact. Gogilidze highlights the key points of the proceedings, which appear to have been mischaracterized in some media reports. Nature of the Court Order: The ruling represents an interim injunction granted at a preliminary procedural stage, not a final determination on the merits of the underlying dispute. Such orders are designed to maintain the status quo pending full trial proceedings. Commercial Impact: The injunction has no practical effect as neither Aviator LLC nor its IP rights licensee had any existing plans to enter
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum